Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma

Inclusion Criteria: * Histopathology and immunohistochemistry confirmed diagnosis of ENKTL according to WHO 2016 criteria. * refractory or relapsed after initial remission, or Ann-Arbor stage III-IV de novo patients * PET/CT or CT/MRI with at least one objectively evaluable lesion. * Expected to survive more than 3 months. * General status ECOG score 0-2 points. * The laboratory test within 1 week before enrollment meets the following conditions: Blood routine: WBC≥3×10e9/L, PLT≥75×10e9/L, ANC≥1.5×10e9/L. sCR≤1.5 mg/dL,GFR≥50 ml/min. Liver function: ALT \& AST≤3 times the upper limit of normal, TBIL ≤2 times the upper limit of normal. Serum fibrinogen level≥1.0 g/L. •Sign the informed consent form Exclusion Criteria: * Patients with CNS involvement, or with other neoplasm; * Patients has received PI3K inhibitor treatment before enrollment * Poor performance status, ECOG≥2; * Patients in lactation or pregnancy； * Patients (male or female) have the possibility of childbirth but are unwilling or have not taken effective contraceptive measures； * Patients allergic to any of the study drugs； * Patients with active infection； * Patients with a history of immunodeficiency, including HIV positive or other acquired or congenital immunodeficiency diseases, or a history of organ transplantation; * Patients with a history of interstitial pneumonia, non infectious pneumonia, or highly suspected interstitial pneumonia; * Patients with a history of neurological or psychiatric disorders, including epilepsy or dementia, in the past * According to the researcher's judgment, there are accompanying diseases that seriously endanger patient safety or affect patient completion of the study.